6-Quinolinecarboxamide, 4-[3-chloro-4-[[(methylamino)carbonyl]amino]phenoxy]-7-methoxy-
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan HospitalSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
48 Active assets in the Hepatocellular Carcinoma (HCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enzalutamide Exelixis | Phase 3 | B |
Icaritin Northern Jiangsu People's Hospital | Phase 3 | B |
Pexastimogene Devacirepvec Transgene | Phase 3 | B |
Biejia-Ruangan Compound Nanfang Hospital, Southern Medical University | Phase 4 | B |
hlx13 Shanghai Henlius Biotech | Phase 3 | B |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →